Evidence map›Paper›PMID 37100925›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2023

Exploring depression in Parkinson's disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management.

Fabrizio Stocchi, Angelo Antonini, Paolo Barone, Giuseppe Bellelli, Andrea Fagiolini, Luigi Ferini Strambi, Sandro Sorbi, Alessandro Padovani

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. [Research progress on repetitive transcranial magnetic stimulation for improving depression in Parkinson's disease].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fabrizio StocchiUniversity San Raffaele Rome and IRCCS San Raffaele, Rome, Italy. fabrizio.stocchi@fastwebnet.it.ORCID http://orcid.org/0000-0002-5763-0033
Angelo AntoniniParkinson and Movement Disorders Unit, Center for Neurodegenerative Diseases (CENSE), Department of Neuroscience, University of Padua, Padua, Italy.ORCID http://orcid.org/0000-0003-1040-2807
Paolo BaroneDepartment of Medicine and Surgery, Neuroscience Section, University of Salerno, Salerno, Italy.
Giuseppe BellelliSchool of Medicine and Surgery, University of Milano-Bicocca, 20126, Milan, Italy.
Andrea FagioliniDepartment of Molecular and Developmental Medicine, University of Siena, School of Medicine, Siena, Italy.
Luigi Ferini StrambiDepartment of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Neurology-Sleep Disorders Centre, Milan, Italy.
Sandro SorbiDepartment of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Alessandro PadovaniDepartment of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression is a prodromic and a frequent non-motor symptom of Parkinson's disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions.

methodsA Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson's disease. RESULTS AND

conclusionExperts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients' characteristics.

Indexed as

Parkinson DiseaseAntidepressive AgentsDelphi TechniqueDepressionHumansQuality of LifeAntidepressive AgentsDelphi ConsensusDepressionMultimodal antidepressantsParkinson’s diseaseSSRI

Identifiers

PMID37100925
PMCPMC10415449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.